Efficacy and safety of 2 doses of agomelatine (10 mg/day or 25 mg/day) versus placebo in generalized anxiety disorder

被引：0

作者：

Stein, D. ^{[1
,2
]}

Ahokas, A. ^{[3
]}

Jarema, M. ^{[4
]}

Avedisova, A. S. ^{[5
]}

Vavrusova, L. ^{[6
]}

Chaban, O. ^{[7
]}

Olivier, V. ^{[8
]}

Gruget, C. ^{[8
]}

Picarel-Blanchot, F. ^{[8
]}

De Bodinat, C. ^{[8
]}

机构：

[1] Univ Cape Town, Cape Town, South Africa

[2] Mt Sinai Sch Med, Dept Psychiat, Cape Town, South Africa

[3] Mehilainen Clin, Dept Psychiat, Helsinki, Finland

[4] Ctr Terapii Dialog, Warsaw, Poland

[5] Psychiat Hosp 12, Moscow, Russia

[6] Univ Hosp Bratislava, Dept Psychiat, Bratislava, Slovakia

[7] Railway Clin Hosp, Psychoneurol Dept, Kiev, Ukraine

[8] Inst Rech Int Servier, Pole Innovat Therapeut Neuropsychiat, Suresnes, France

来源：

EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2016年 / 26卷

关键词：

D O I：

10.1016/S0924-977X(16)31678-9

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P.4.b.003

引用

页码：S601 / S602

页数：2

共 50 条

[41] Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial [J].

Daniel, DG ;

Zimbroff, DL ;

Potkin, SG ;

Reeves, KR ;

Harrigan, EP ;

Lakshminarayanan, M .

NEUROPSYCHOPHARMACOLOGY, 1999, 20 (05) :491-505

[42] Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder: A 6-Week Placebo-Controlled Trial [J].

David G Daniel ;

Dan L Zimbroff ;

Steven G Potkin ;

Karen R Reeves ;

Edmund P Harrigan ;

Mani Lakshminarayanan .

Neuropsychopharmacology, 1999, 20 :491-505

[43] DOUBLE-BLIND COMPARISON OF BUSPIRONE 10 MG BID VERSUS BUSPIRONE-5 MG TID IN GENERALIZED ANXIETY DISORDER [J].

FONTAINE, R ;

NAPOLIELLO, MJ .

CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1993, 54 (02) :254-261

[44] Efficacy of agomelatine in generalized anxiety disorder: A randomized, double-blind, placebo-controlled study [J].

Stein, Dan J. ;

Ahokas, Antti A. ;

de Bodinat, Christian .

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2008, 28 (05) :561-566

[45] A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder [J].

Colonna, L ;

Andersen, HF ;

Reines, EH .

CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (10) :1659-1668

[46] Crossover clinical study comparing the pharmacokinetics of etoposide (75 mg) administered as 25-mg capsules three times a day versus once a day [J].

Aydiner, A ;

Koyuncu, H ;

Tas, F ;

Topuz, E ;

Disci, R .

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 2000, 20 (1-2) :21-30

[47] Functional outcome in patients with major depressive disorder treated by agomelatine 25-50 mg as compared to placebo [J].

Kennedy, S. H. ;

Heun, R. ;

Avedisova, A. S. ;

Ahokas, A. ;

Olivier, V. ;

Picarel-Blanchot, F. ;

De Bodinat, C. .

EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 :S233-S234

[48] Efficacy and safety of once daily gliclazide (20 mg/day) compared with nateglinide [J].

Miwa, S ;

Watada, H ;

Ohmura, C ;

Tanaka, Y ;

Kawamori, R .

ENDOCRINE JOURNAL, 2004, 51 (04) :393-398

[49] Multicenter double-blind randomized parallel-group clinical trial of efficacy of the combination clomipramine (150 mg/day) plus lithium carbonate (750 mg/day) versus clomipramine (150 mg/day) plus placebo in the treatment of unipolar major depression [J].

Januel, D ;

Poirier, MF ;

D'alche-Biree, F ;

Dib, M ;

Olié, JP .

JOURNAL OF AFFECTIVE DISORDERS, 2003, 76 (1-3) :191-200

[50] Safety and Efficacy of Eltrombopag (EPAG) at Doses up to 150 mg/day in Children with Chronic Immune Thrombocytopenia (cITP) Who did not Achieve Target Platelet Counts (PLTS) with 75 mg/day dose [J].

Keefe, Peter ;

Rocha, Arelys ;

Bussel, James .

PEDIATRIC BLOOD & CANCER, 2017, 64 :S10-S10

← 1 2 3 4 5 →